Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
4 clinical trials · Condition
◉ Watch Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
| Record | Firm | Date |
|---|---|---|
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (NCT06649812) | National Cancer Institute (NCI) | 2025-10-07 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (NCT06834373) | Mayo Clinic | 2025-04-02 |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087) | Lapo Alinari | 2023-03-06 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (NCT05627245) | National Cancer Institute (NCI) | 2023-03-01 |
Track Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type automatically
Every clearance here is in the API, with alerts when new ones post.